AlphAIalphai — Financial news for AI agents
GlobeNewswireOCT 312 min read$COHN

Cohen & Company Sets Release Date for Third Quarter 2025 Financial Results

PHILADELPHIA and NEW YORK, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Cohen & Company Inc. ( NYSE American: COHN ) will release its financial results for the third quarter 2025 on Tuesday, November 4, 2025. The Company will host a conference call at 10:00 a.m. Eastern Time ( ET ) that day to discuss ...

Original reporting
GlobeNewswire · Cohen & Company Inc.
Published Oct 31, 2025, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 31, 2025, 8:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Cohen & Company Sets Release Date for Third Quarter 2025 Financial Results — source image
Source · www.globenewswire.com
Decision brief

The 30-second read

$COHNNeutralMed
01

Why it matters

The upcoming earnings release is a key event that could influence the company's stock price and investor sentiment.

02

Market read

The event is highly relevant for investors and traders focusing on the financial sector, especially those holding or considering positions in COHN.

03

What to watch

Broader market trends and macroeconomic factors could overshadow company-specific news, reducing the impact of earnings on stock performance.

Timing: High, as the earnings release is scheduled for November 4, 2025.

Background

Cohen & Company Inc. is a financial services firm scheduled to announce its Q3 2025 financial results.

Company-level read

Ticker impact

$COHNNeutralMedium confidence
Context

Primary focus due to company's upcoming earnings release.

Expected impact

Potential short-term increase or decrease depending on earnings results; no definitive movement expected prior to release.

Evidence & confidence

Earnings releases are significant catalysts; however, without prior earnings estimates or consensus data, the market reaction remains uncertain.

Market effects

Sector

The earnings report may influence investor sentiment within the financial services sector.

Regional

Limited regional impact expected; primarily affecting US-based investors.

Global

Minimal global market relevance, as the event pertains to a single company's earnings.

Counterpoint

What could challenge this read

Earnings results may be in line with expectations, leading to minimal stock movement.

Key entities

  • Company
    Cohen & Company Inc.

    A financial services firm listed on NYSE American.

Read at source← All news

Related articles

AUG 3
$COHNMed

Cohen & Co Inc. (COHN): Results of Operations and Financial Condition

Cohen & Co Inc. (COHN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 COHEN & COMPANY REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Board Declares Quarterly Dividend of $0.25 per Share Revenue of $69.5 Million Net Income Attributable to Cohen & Company Inc. of $3.6 Million, or $0.94 per Diluted Share Adjusted Pre-Tax Income of $10.1 Mi

SEC EDGAR 8-K6 min
JUN 26
$CMIIMedAI 8/10

2026 - 06 - 26 | Elroy Air to Become Publicly Traded Company via Business Combination with Inflection Point - led SPAC | NDAQ: CMII

Elroy Air will become a publicly traded company through a business combination with SPAC Columbus Circle Capital Corp II (Nasdaq: CMII), led by Inflection Point Asset Management. The deal values Elroy Air at about $800M pre-money and ~$1.0B enterprise value, with $165M+ committed PIPE capital. Closing is expected in Q4 2026. Elroy’s Chaparral VTOL drone targets 500+ lbs cargo; demand pipeline exceeds 1,400 aircraft and $5B potential revenue.

stockhouse.com6 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min
SEP 8
$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

theyeshivaworld.com2 min
SEP 8
$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.

yahoo.com2 min